Halozyme Therapeutics (HALO)
(Delayed Data from NSDQ)
$64.42 USD
+1.22 (1.93%)
Updated Aug 28, 2024 04:00 PM ET
After-Market: $64.96 +0.54 (0.84%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth B Momentum C VGM
Company Summary
San Diego, CA-based Halozyme Therapeutics is a biopharmaceutical company, focused on the development and commercialization of novel treatments for oncology indications by targeting tumor microenvironment. The company also licenses its novel drug delivery technology, ENHANZE, for subcutaneous (SC) administration of drugs.
The company’s ENHANZE drug delivery technology helps in developing SC formulation of drugs. Several companies including Roche, Takeda, J&J, AbbVie, Lilly, Bristol-Myers and others are using this technology for developing SC formulation of their currently marketed drugs.It also recognizes revenues from the sale of drug ...
Company Summary
San Diego, CA-based Halozyme Therapeutics is a biopharmaceutical company, focused on the development and commercialization of novel treatments for oncology indications by targeting tumor microenvironment. The company also licenses its novel drug delivery technology, ENHANZE, for subcutaneous (SC) administration of drugs.
The company’s ENHANZE drug delivery technology helps in developing SC formulation of drugs. Several companies including Roche, Takeda, J&J, AbbVie, Lilly, Bristol-Myers and others are using this technology for developing SC formulation of their currently marketed drugs.It also recognizes revenues from the sale of drug products to its collaboration partners for the development of drugs using its ENHANZE platform. The company currently earn royalties on sales of seven commercial products by its partners. The ENHANZE platform was developed based on the company’s patented recombinant human hyaluronidase enzyme (rHuPH20).
In May 2022, Halozyme acquired Antares Pharma which added an industry-leading auto-injector platform and a commercial business with two proprietary products to Halozyme’s portfolio.
The company’s portfolio of products include — Hylenex Recombinant and Xyosted.
Halozyme derives the majority of its revenues from royalties on sales of partnered drugs. The company generated total revenues of $829.3 million in 2023, up 26% year over year.
General Information
Halozyme Therapeutics, Inc
12390 EL CAMINO REAL
SAN DIEGO, CA 92130
Phone: 858-794-8889
Fax: 858-704-8311
Email: ir@halozyme.com
Industry | Medical - Biomedical and Genetics |
Sector | Medical |
Fiscal Year End | December |
Last Reported Quarter | 6/30/2024 |
Exp Earnings Date | 11/4/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | 0.99 |
Current Year EPS Consensus Estimate | 3.90 |
Estimated Long-Term EPS Growth Rate | 28.00 |
Exp Earnings Date | 11/4/2024 |
Price and Volume Information
Zacks Rank | ![]() |
Yesterday's Close | 63.20 |
52 Week High | 63.49 |
52 Week Low | 32.83 |
Beta | 1.27 |
20 Day Moving Average | 1,336,546.38 |
Target Price Consensus | 59.10 |
4 Week | 13.48 |
12 Week | 42.66 |
YTD | 71.00 |
4 Week | 9.67 |
12 Week | 34.18 |
YTD | 44.98 |
Shares Outstanding (millions) | 126.68 |
Market Capitalization (millions) | 8,006.07 |
Short Ratio | NA |
Last Split Date | NA |
Dividend Yield | 0.00% |
Annual Dividend | $0.00 |
Payout Ratio | 0.00 |
Change in Payout Ratio | 0.00 |
Last Dividend Payout / Amount | NA / $0.00 |
Fundamental Ratios
P/E (F1) | 16.20 |
Trailing 12 Months | 19.33 |
PEG Ratio | 0.58 |
vs. Previous Year | 25.00% |
vs. Previous Quarter | 19.72% |
vs. Previous Year | 4.67% |
vs. Previous Quarter | 18.11% |
Price/Book | 27.79 |
Price/Cash Flow | 19.89 |
Price / Sales | 9.17 |
6/30/24 | 195.80 |
3/31/24 | 225.71 |
12/31/23 | 248.20 |
6/30/24 | 21.07 |
3/31/24 | 20.52 |
12/31/23 | 19.13 |
6/30/24 | 7.41 |
3/31/24 | 6.64 |
12/31/23 | 6.64 |
6/30/24 | 6.21 |
3/31/24 | 5.36 |
12/31/23 | 5.50 |
6/30/24 | 44.85 |
3/31/24 | 43.27 |
12/31/23 | 41.15 |
6/30/24 | 38.62 |
3/31/24 | 36.94 |
12/31/23 | 33.96 |
6/30/24 | 47.72 |
3/31/24 | 45.44 |
12/31/23 | 42.01 |
6/30/24 | 2.28 |
3/31/24 | 1.40 |
12/31/23 | 0.63 |
6/30/24 | 1.20 |
3/31/24 | 1.33 |
12/31/23 | 1.55 |
6/30/24 | 5.19 |
3/31/24 | 8.44 |
12/31/23 | 17.89 |
6/30/24 | 83.85 |
3/31/24 | 89.41 |
12/31/23 | 94.71 |